Aim of this study is to investigate the effect of early administration of anti-thymocyte globulin and post-transplant low-dose cyclophosphamide in heploidentical hematopoietic stem cell transplantation.
Hematopoietic stem cell transplantation from a haploidentical donor (haplo-HCT) are increasingly used in patients lacking a matched donor, but the optimal strategy needs to be defined. This study aims to investigate the outcome of haplo-HCT with early antithymocyte globulin and low dose posttransplant cyclophosphamide (ATG/LD-PTCy) in a single center.
Study Type
OBSERVATIONAL
Enrollment
20
antithymocyte globulin with low dose post-transplant cyclophosphamide
Samsung Medical Center
Seoul, South Korea
RECRUITINGEmgraftment Rate
cumulative incidence of donor-dominant engraftment by day 28 (by case)
Time frame: From the date of transplantation until 28 days after transplantation
Time to Engraftment
median time to neutrophil engraftment
Time frame: From the date of transplantation until first neutrophil count over 500/uL for 3 consecutive tays
Acute Graft-Versus-Host Disease
Incidence of acute GVHD ≥ grade 2
Time frame: From the date of transplantation until 365 days after transplantation
Chronic Graft-Versus-Host Disease
Incidence of moderate to severe chronic GVHD
Time frame: From the date of transplantation until the date of documentation of highest level of chronic GVHD, assessed up to 2 years after transplantation
Rate of CMV infection
Rate of CMV infection
Time frame: From the date of transplantation until 365 days after transplantation
Rate of Hemorrhagic Cystitis
Rate of Hemorrhagic Cystitis
Time frame: From the date of transplantation until 365 days after transplantation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.